47 results about "Dextran Derivatives" patented technology

The present invention relates to one kind of environment responding aquogel copolymer and its preparation process. The aquogel consists of: N-isopropyl acrylamide 10-90 wt% and methacrylate dextran derivative 10-90 wt%. The preparation process of the environment responding aquogel copolymer includes chemical modification of dextran with GMA to synthesize methacrylate dextran derivative, MA-Dex, with reaction activity; and subsequent copolymerization of MA-Dex and NIPA to obtain the said environment responding aquogel copolymer P(NIPA-co-MA-Dex). The aquogel copolymer has high temperature sensitivity and quick responding speed as well as high strength and excellent biocompatibility. The preparation process is simple, needs no special apparatus and is easy to realize in industry.

The invention concerns a biologically active material essentially comprising at least an insolubilized dextran derivative of general formula DMCaBbSUcSd and at least a growth factor having an activity on osteoarticular, dental and / or maxillofacial tissues, and the method for preparing same. The invention also concerns the uses of said biomaterial for preparing a repair or filing material, such as an implant, for osteoarticular, dental or maxillofacial applications and for preparing an orthopaedic, dental or maxillofacial prosthesis, and the prosthesis coated with said biologically active material.

The invention discloses a new method for preparing an intelligent glucose-sensitive insulin controlled-release biological material. The method comprises the following steps of: firstly, dissolving glucose derivative monomers with C=C derivatives and concanavalin A derivative monomers with C=C double bonds in buffer solution to produce monomer solution; secondly, adding a catalyst in the monomer solution to perform free radical polymerization at a certain temperature; and finally, removing unreacted reactant through dialysis to obtain the glucose-sensitive insulin controlled-release biologicalmaterial. The preparation method has the advantages of convenient implementation, fast reaction process, mild reaction condition and easy production preparation on a large scale. The obtained glucan-concanavalin A insulin controlled-release biological carrier material has the advantages of good glucose-sensitive property and excellent insulin controlled-release performance.

A glucan derivative (e.g., a cellulose acylate derivative) which is useful for a thermoplastic resin, is inhibited in hygroscopicity at a high level and is excellent in compatibility with a plasticizer or solubility in a solvent is provided. In the glucan derivative which comprises an acyl group and a graft chain formed from at least one graft component selected from a lactone and a hydroxycarboxylic acid, each bonding to a glucose unit of a glucan (e.g., a cellulose) constituting the glucan derivative, a hydroxyl group in the graft chain is protected with a protecting group. The graft chain may be formed from a C4-16lactone. The hydroxyl group in the graft chain may be protected with an acyl group (e.g., a C2-8alkylcarbonyl group such as acetyl group). The degree of substitution of the acyl group may be from 1 to 2.99, and the degree of substitution of the graft chain may be from 0.01 to 2.

An object of the present invention is to provide a β-1,3-glucan derivative which is a polymer having β-1,3-glucan as a main chain, and has thermoplasticity and excellent moldability, and a preparation method thereof. That is, the present invention provides a β-1,3-glucan derivative having a structure represented by General Formula (1) as a main chain.(In Formula (1), each of a plurality of R1s independently represents a hydrogen atom or —COR2, n represents an integer of 1 or greater, and R2 represents an aliphatic hydrocarbon group or an aromatic hydrocarbon group. In Formula (1), a plurality of the R1s may be the same as or different from each other, and at least a part of a plurality of the R1s is —COR2.)

The invention discloses a yeast beta-D-glucan derivative and a preparation method and an application thereof. The yeast beta-D-glucan derivative is obtained by substituting the hydroxyl of a yeast beta-D-glucan molecule with a sulfate group, wherein the degree of substitution of the sulfate group is 0.28-0.32 or 0.40-0.51. The invention further provides a method for preparing the yeast beta-D-dextran derivative, which comprises the following steps: dissolving yeast beta-D-glucan into an organic solvent and adding an esterifying agent for esterification reaction to obtain the yeast beta-D-dextran derivative. The contrastive analysis of a scanning electron microscopy discovers that the sulfated and modified yeast beta-D-glucan derivative is in a grid shape and has obvious grooves, the specific surface area is obviously increased, and the adsorption capacity is remarkably enhanced. An adsorption effect test shows that the adsorption quantity of zearalenone by the yeast beta-D-glucan derivative reaches 18.6528 mug / mg and is remarkably higher than that of the zearalenone by a yeast cell wall and the yeast beta-D-glucan.

A process for producing a glucan derivative modified with a cyclic ester with a highly suppressed homopolymerization of a cyclic ester is provided.In a production process for a modified glucan derivative, by allowing a glucan derivative having a hydroxyl group to react with a cyclic ester in a solvent in the presence of a ring-opening polymerization catalyst to give a modified glucan derivative in which the cyclic ester is graft-polymerized to the glucan derivative, (1) the ring-opening polymerization catalyst is a metal complex which by itself does not initiate the polymerization of the cyclic ester; and (2) the solvent comprises a nonaromatic hydrocarbon solvent having a solubility in water of not more than 10% by weight at 20° C.

The present invention discloses a degradable polymer microcapsule injection preparation of oil-soluble medicine and its preparation method. It uses polysaccharide containing double-bond and polylactic acid which have good biological compatibity and biological degradability as capsule shell material, adopts O / W emulsion polymerization technique and controls the ratio of mixing polysaccharide and polylactic acid to obtain the invented medicine microcapsule injection preparation whose grain size is 100-3000 nm.

The invention belongs to the field of biomedical science, and particularly relates to a preparation method of injectable self-curing hypoglycemic hydrogel. The preparation method is characterized in that dextran (Dex) and polyethylene glycol (PEG) are used as main raw materials and are subjected to chemical modification so as to obtain derivatives of the dextran and the polyethylene glycol, namely the furyl dextran derivative (DF) and the maleimide polyethylene glycol (Mal-PEG-Mal) derivative, the self-curing hydrogel material controlled in gelling time can be obtained through Diels-Alder reaction, and a hypoglycemic medicament comprising one or more of sulfonylureas, biguanides, insulin and the like is loaded on the hydrogel material. The purpose of stably controlling blood sugar for a long time is achieved by slowly releasing the hypoglycemic medicament, the morbidity of diabetic complications is reduced, and even the life span of patients is prolonged.

The invention discloses a glucan-based nanogel. Glucan is taken as a framework material, vinyl ether acrylate modification is carried out to obtain a glucan derivative I, then based on the glucan derivative I, sulfydryl modification and carboxyl modification are carried out respectively to obtain a glucan derivative II and a glucan derivative III, and the glucan derivative II and the glucan derivative III are mixed for a Michael addition reaction to obtain the glucan-based nanogel. Compared with the prior art, the obtained glucan-based nanogel contains acid-sensitive acetal groups, targeted release is achieved by utilizing the enhanced permeation and retention (EPR) of a solid tumor and the meta-acidic microenvironment at a tumor site, completely different antitumor strategies of two mechanisms comprising the chemotherapy and photodynamic therapy are combined, through the synergistic effect, the antitumor effect is improved, and the toxic and side effects of a chemotherapy drug are effectively reduced.

The invention discloses a preparation method of a yeast beta-1,3-D-glucan derivative. Puffing technology and acid-base solution treatment are combined in the method to prepare the yeast beta-1,3-D-glucan derivative, so that the time for preparing the yeast beta-1,3-D-glucan can be greatly saved, and the extraction cost can be reduced.

Disclosed is a method for producing a cyclic ester-modified glucan derivative wherein generation of homopolymers of the cyclic ester can be highly suppressed. Specifically disclosed is a method for producing a modified glucan derivative to which a cyclic ester is graft-polymerized, wherein a glucan derivative having a hydroxyl group and a cyclic ester are reacted in a solvent in the presence of a ring-opening polymerization catalyst. In this method, (1) the ring-opening polymerization catalyst is composed of a metal complex which does not initiate polymerization of the cyclic ester by itself; (2) the solvent is composed of an aromatic hydrocarbon solvent having a solubility in water at 20° C. of not more than 10% by weight; and (3) the ratio of the solvent is set at not less than 60 parts by weight per 100 parts by weight of the glucan derivative having a hydroxyl group.

The invention concerns pharmaceutical compositions with wound healing or anti-complementary activity, and their uses, said compositions comprising, (1) at least a dextran derivative of general formula DMCaBbSuc, a, b, and c respectively representing the degrees of substitution in the groups MC, B and Su, wherein a≧0.6, b=0 or ≧0.1, and c=0 or ranges widely between 0.1 and 0.5 for a wound healing composition, and a≧0.3, b≧0.1 and c=0 or ranges widely between 0.1 and 0.4 for a composition with anti-complementary activity; (2) and at least a pharmaceutically acceptable carrier, said dextran derivative being present in a single unit dose or at a concentration adapted to the desired wound healing or anti-complementary activity.

This invention discloses new immobilized trypsin and its producing method. Compatible immobilized enzyme carrier that synthesized by dextran derivative is used, enzyme and carrier are used to produce the fixed trypsin by crosslinking agent, the enzyme activity of immobilized trypsin is 60 to 85 percent of non immobilized, activity recovery is 60 to 85 percent. The material is easy to gain, operation is simple, the immobilized trypsin has good stability, it can be repeated used, it can be dissolved in substrate solution and react with solid substrate, its catalysis efficiency is high, and has good application value.

The invention relates to a thioctic acid-glucan conjugate, a preparation method and the usage thereof. The functional thioctic acid-glucan conjugate is designed and synthesized by taking glucan as rawmaterial, and the degree of substitution of thioctic acid on the glucan is 0.1-50% based on the weight percent. The active carboxyl contained by the thioctic acid and the hydroxy on the glucan can bedirectly esterified, and the thioctic acid-glucan conjugate can be prepared. By controlling different degrees of substitution of the thioctic acid, glucan derivatives having different properties canbe obtained. The thioctic acid-glucan conjugate can be taken as thioctic acid polymer drug and novel pharmaceutic adjuvant.

The invention provides a modified glucan derivative (e.g., modified cellulose acylate) which is suitable for use in optical applications such as optical films. The modified glucan derivative comprises a glucan derivative (e.g., cellulose acetate) and a hydroxy acid ingredient graft-polymerized therewith, wherein (1) the hydroxy acid ingredient comprises a lactone, (2) the hydroxy acid ingredient comprises an a-hydroxy acid ingredient (e.g., lactic acid or lactide) and the proportion of the hydroxy acid ingredient graft-polymerized is 0.1-5 mol on the average in terms of hydroxy acid amount per mol of the glucose units constituting the glucan derivative, or (3) the proportion of the hydroxy acid ingredient by which the glucan derivative is substituted, degree of polymerization of the graft chains, degree of substitution of the glucan derivative (e.g., degree of acetyl substitution), etc. are regulated, whereby the modified glucan derivative has a glass transition temperature of 70 DEG C or higher.

A process for producing a glucan derivative modified with a cyclic ester with a highly suppressed homopolymerization of a cyclic ester is provided. In a production process for a modified glucan derivative, by allowing a glucan derivative having a hydroxyl group to react with a cyclic ester in a solvent in the presence of a ring-opening polymerization catalyst to give a modified glucan derivative in which the cyclic ester is graft-polymerized to the glucan derivative, (1) the ring-opening polymerization catalyst is a metal complex which by itself does not initiate the polymerization of the cyclic ester; (2) the solvent comprises an aromatic hydrocarbon solvent having a solubility in water of not more than 10% by weight at 20 DEG C; and (3) the proportion of the solvent is not less than 60 parts by weight relative to 100 parts by weight of the glucan derivative having a hydroxyl group.

The invention discloses a 1,3-beta-D glucan derivative, a kit, a preparation method and a method for determining the content of 1,3-beta-D glucan. The invention provides a 1,3-beta-D glucan magnetic particle chemiluminiscence immunoassay kit which combines a magnetic particle separation technology, a biotin-avidin amplification technology and a chemiluminiscence analysis technology. Meanwhile, a biotinylated 1,3-beta-D glucan antigen derivative and an enzyme-labeled 1,3-beta-D glucan antigen derivative are prepared from the 1,3-beta-D glucan antigen derivative, so that two systems (1, the biotinylated 1,3-beta-D glucan antigen derivative plus an antibody enzyme-labeled reagent and plus a calibration solution; 2, the enzyme-labeled 1,3-beta-D glucan antigen derivative plus a biotinylated 1,3-beta-D glucan mouse monoclonal antibody and plus calibration liquid) are constructed, and the 1,3-beta-D glucan in a sample can be tested, so that different enterprises have more flexible selection when developing the kit, and the kit can be realized by only preparing the intermediate, namely, the 1,3-beta-D glucan antigen derivative.

A fluid viscosified with diutan or scleroglucan is provided for use in a well, the fluid including: (i) water; (ii) one or more salts selected from the group consisting of alkali metal halide salts, alkaline earth metal halide salts, and any combination thereof; (iii) a viscosifier selected from the group consisting of diutan, a diutan derivative, scleroglucan, a scleroglucan derivative, and any combination thereof; and (iv) a delayed-release source of a weak acid; wherein the initial pH of the fluid is at least 6. In addition, a method of treating a portion of a well includes the steps of: (A) forming such a fluid; and (B) introducing the fluid into the portion of the well. The fluid has rheological properties that can be adapted, for example, to well treatments such as gravel packing at higher temperature and in higher density brines while avoiding salting out of the viscosifier.

The invention provides a pharmaceutical composition for mild photothermal therapy of tumors as well as a preparation method and application of the pharmaceutical composition. The pharmaceutical composition is composed of a dual-targeting amphiphilic glucan derivative carrier, a material (PTA) with photo-thermal conversion performance and an autophagy inhibitor. The dual-targeting amphiphilic glucan derivative carrier can be self-assembled in water to form nano-micelles, and is physically loaded with PTA and an autophagy inhibitor for tumor photothermal therapy. The preparation is mainly characterized in that: 1) the preparation has active dual-targeting capability of tumor cells and tumor-related fibroblasts, and can efficiently enter the cells through the action of receptor ligands, so that the transfer efficiency of the preparation is improved; 2) under the irradiation of 808nm laser, PTA absorbs light energy and efficiently converts the light energy into heat, and the autophagy inhibitor inhibits the autophagy behavior of tumor cells and sensibilizes photo-thermal, so that an excellent mild photo-thermal treatment effect is realized, and the physical barrier of a tumor matrix can be weakened; tumor photothermal can further induce tumor cells to generate immunogenic cell death, generated tumor fragments can further activate an immune system, and the tumor photothermal treatment effect is greatly improved.

The invention provides an amphiphilic dextran derivative carrier for targeting tumor-associated fibroblasts and preparation and application of a pharmaceutical composition of the amphiphilic dextran derivative carrier. The amphiphilic dextran derivative carrier comprises a derivative skeleton modified by hydrophilic dextran carboxyl, an FAP-alpha responsive peptide fragment connecting arm and a hydrophobic group molecule. The amphiphilic derivative is self-assembled in an aqueous solution to form nanoparticles, and molecules with pharmacological activity can be physically loaded for tumor treatment. The amphiphilic dextran derivative carrier is mainly characterized in that: (1) after the nanoparticles reach a focus part, a specific peptide fragment connecting arm can be subjected to enzyme digestion by FAP-alpha which is specifically and highly expressed on the surface of tumor-associated fibroblasts, so that the nanoparticles are rapidly degraded; and (2) the pharmacological active molecules which are physically loaded are quickly released from the disintegrated nanoparticles, tumor-associated fibroblasts can be effectively killed or the function thereof can be inhibited, the physical barrier of a tumor matrix can be weakened, and the permeation of an anti-tumor preparation can be promoted when the nano-particles are combined with other anti-tumor preparations, so that the treatment effect of the anti-tumor preparation can be effectively improved.

An object of the present invention is to provide a β-1,3-glucan derivative which is a polymer having β-1,3-glucan as a main chain, and has thermoplasticity and excellent moldability, and a preparation method thereof. That is, the present invention provides a β-1,3-glucan derivative having a structure represented by General Formula (1) as a main chain.(In Formula (1), each of a plurality of R1s independently represents a hydrogen atom or —COR2, n represents an integer of 1 or greater, and R2 represents an aliphatic hydrocarbon group or an aromatic hydrocarbon group. In Formula (1), a plurality of the R1s may be the same as or different from each other, and at least a part of a plurality of the R1s is —COR2.)

The present invention discloses a degradable polymer microcapsule injection preparation of water soluble medicine and its preparation method. It uses polysaccharide containing double-bond and polylactic acid which have good biological compatibility and biological degradability as capsule shell material, utilizes the control of ratio of mixing polysaccharide and polylactic acid and adopts W10 / w emulsion polymerization technique to obtain the medicine microcapsule injection preparation whose grain size is 100-2000nm.

A β-glucan derivative comprising a β-glucan residue of three or more glucose residues and, chemically bonded to the β-glucan residue, a non-reducing sugar residue.

The invention discloses a glucan derivative and an additive containing the glucan derivative. The glucan derivative has a structure as shown in formula I which is described in the specification. According to the glucan derivative disclosed by the invention, two fatty acid ester groups are bonded to the tail end reduction end of dextran bya proper linking group, so that the amphiphilic glucan derivative disclosed by the invention is provided witha double-tail structure, and then the amphiphilic derivative with good biodegradability and good surface activity is obtained and can be widely appliedto pharmaceutical preparations.

The invention relates to the field of medical preparations, in particular to fluorescence specific nanometer iron oxide hybrid dispersion liquid for cancer metastatic lymph node tracing as well as a preparation method and a purpose of the fluorescence specific nanometer iron oxide hybrid dispersion liquid. The fluorescence specific nanometer iron oxide hybrid dispersion liquid for cancer metastatic lymph node tracing comprises a dextran derivative, iron oxide particles and water; the dextran derivative is combined with the iron oxide particles to form a nanometer iron oxide hybrid which is uniformly dispersed in the water and is prepared from the dextran derivative and ferric salt through a coprecipitation method; and the dextran derivative is prepared from 5-aminolevulinic acid and oxidized dextran through Schiff base reaction. The prepared fluorescence specific nanometer iron oxide hybrid dispersion liquid is hopeful to be applied to evaluation of gastrointestinal cancer metastatic lymph nodes and can be coupled to an anti-tumor drug through function derivatization of dextran so as to realize the purpose of diagnosis and treatment integration.

The present invention provides a composition comprising a polysaccharide to enhance transfection of a cell with a nucleic acid. The present invention also provides a method for transfecting a cell with a nucleic acid comprising the steps of forming a polyionic complex of the nucleic acid and a polysaccharide; and bringing about uptake of the polyionic complex by the cell. Preferably, the cell is selected from bone marrow mesenchymal stem cells, nervous system cell lines, adipose tissue stem cells, immunocytes, neurons, and chondrocytes. Moreover, preferably the polysaccharide is a cationized pullulan derivative, a cationized dextran derivative, or a cationized mannan derivative.